<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02722590</url>
  </required_header>
  <id_info>
    <org_study_id>E2007-M065-505</org_study_id>
    <nct_id>NCT02722590</nct_id>
  </id_info>
  <brief_title>A Study of Fycompa (Perampanel) in Korean Participants</brief_title>
  <official_title>Post-Marketing Surveillance of Fycompa in Korean Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this post-marketing surveillance is to observe the following items regarding&#xD;
      the safety profile of Fycompa (Perampanel) film-coated tablets and oral suspension in normal&#xD;
      clinical practice setting: serious adverse event/adverse drug reaction profile, unexpected&#xD;
      adverse event/adverse drug reaction profile, already known adverse drug reaction profile,&#xD;
      non-serious adverse event profile and other information related to the product's safety and&#xD;
      effectiveness.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2016</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>From the first Fycompa (Perampanel) administration date up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions</measure>
    <time_frame>From the first Fycompa (Perampanel) administration date up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unexpected Adverse Events</measure>
    <time_frame>From the first Fycompa (Perampanel) administration date up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>From the first Fycompa (Perampanel) administration date up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Effective Outcome as Measured by Investigator's Clinical Global Impression of Change (CGI-C) Scores</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The CGI-C score is a clinician's rating scale for assessing Global Improvement of Change. The CGI-C rates improvement by 7 categories: very much improved (1), much improved (2), minimally improved (3), no change (4), minimally worse (5), much worse (6), very much worse (7). The CGI-C score ranges from 1 to 7, with lower scores indicating improvement. Effective outcome is defined as CGI-C score of: very much improved (1), much improved (2), or minimally improved (3).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">3692</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>All Participants</arm_group_label>
    <description>Participants who are prescribed Fycompa (Perampanel) film-coated tablets and oral suspension per approved prescribing information in a normal clinical practice setting will be enrolled and observed prospectively for up to 24 Weeks.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female Korean participants who are prescribed with Fycompa (Perampanel) per the&#xD;
        approved prescribing information will be enrolled in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants with approved indication for Fycompa (Perampanel) in Korea as follows:&#xD;
&#xD;
               -  Monotherapy (film-coated tablets)&#xD;
&#xD;
                  o 4 years and older Partial-onset seizures: therapy for treatment of&#xD;
                  partial-onset seizures with or without secondarily generalized seizures in&#xD;
                  participants with epilepsy&#xD;
&#xD;
               -  Adjunctive therapy (film-coated tablets &amp; oral suspension)&#xD;
&#xD;
                    -  4 years and older Partial-onset seizures: therapy for treatment of&#xD;
                       partial-onset seizures with or without secondarily generalized seizures in&#xD;
                       participants with epilepsy&#xD;
&#xD;
                    -  7 years and older Primary generalized tonic-clonic seizures: therapy for&#xD;
                       treatment of primary generalized tonic-clonic seizures in participants with&#xD;
                       idiopathic generalized epilepsy&#xD;
&#xD;
          2. Participants who have written consent for use of personal and medical information for&#xD;
             the study purpose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to the active substance or to any of the excipients of this medicine&#xD;
&#xD;
          2. In case of Fycompa film-coated tablets, Fycompa tablets contains lactose; therefore,&#xD;
             participants with rare hereditary problems of galactose intolerance, the Lapp lactase&#xD;
             deficiency, or glucose-galactose malabsorption should not take this medicine. In case&#xD;
             of Fycompa oral suspension, Fycompa suspension contains sorbitol; therefore,&#xD;
             participants with rare hereditary problems of fructose intolerance should not take&#xD;
             this medicine.&#xD;
&#xD;
          3. Other participants judged to be inadequate to participate in the study by doctor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Chungju</city>
        <state>Chungcheong-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggji-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinju</city>
        <state>Gyeongsang-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <state>Jeolla-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2016</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Partial-onset seizures</keyword>
  <keyword>Secondarily generalized seizures</keyword>
  <keyword>Perampanel</keyword>
  <keyword>Post marketing surveillance</keyword>
  <keyword>Primary generalized tonic-clonic seizures</keyword>
  <keyword>Idiopathic generalized epilepsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

